Q-omics provides the consensus-scored TSHR profile across patient tissues and cancer cell-line models. TSHR expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TSHR is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TSHR RNA expression shows 16,095 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, THCA, and UVM as cancer lineages where TSHR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSHR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSHR survival associations across molecular data types. TSHR RNA expression shows survival associations in the most cancer types (30), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSHR RNA expression–survival associations across cancer types. High TSHR expression shows unfavorable associations in UCEC, but favorable associations in SKCM, HNSC, LUAD, CESC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TSHR RNA expression.
This table summarizes TSHR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TSHR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSHR shows lower tumor expression in THCA, COAD, UCEC and BRCA and higher tumor expression in KIRC and LUAD. The THCA box plot shows higher TSHR RNA expression in normal versus tumor tissue (log2 FC = −1.163, t-test p < 0.001).
This table shows molecular features associated with TSHR in patient tissues and cancer cell lines. In patient samples, TSHR shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSHR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
